Viridian Therapeutics (NASDAQ:VRDN) Announces Quarterly Earnings Results

Viridian Therapeutics (NASDAQ:VRDN) announced its earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24, Zacks reports. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million.

Viridian Therapeutics Stock Up 1.6 %

NASDAQ VRDN opened at $15.53 on Friday. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The company has a market cap of $1.23 billion, a P/E ratio of -3.60 and a beta of 1.32. The business has a fifty day moving average price of $18.20 and a 200 day moving average price of $19.63. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VRDN. Royal Bank of Canada increased their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.